Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster (Q83117567)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20199763%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20199763%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

4

Gaston De Serres

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20199763%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Marc Brisson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20199763%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Gurgen Melkonyan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20199763%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Melanie Drolet

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20199763%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Roseline Thibeault

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20199763%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Philippe De Wals

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20199763%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 March 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20199763%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20199763%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20199763%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20199763%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

3385-3397

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20199763%20AND%20SRC:MED&resulttype=core&format=json

Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles.

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Postlicensure study of varicella vaccine effectiveness in a day-care setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Ten year follow-up of healthy children who received one or two injections of varicella vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Modelling the impact of immunization on the epidemiology of varicella zoster virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Varicella disease after introduction of varicella vaccine in the United States, 1995-2000

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Impact of varicella vaccination on health care outcomes in Ontario, Canada: Effect of a publicly funded program?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Impact of varicella vaccination on health care utilization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Evaluation of the impact of an HMO's varicella vaccination program on incidence of varicella

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

The changing epidemiology of chickenpox in Alberta.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Chickenpox outbreak in a highly vaccinated school population

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

inferred from DOI database lookup

7 January 2021

based on heuristic

An elementary school outbreak of varicella attributed to vaccine failure: policy implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

The effectiveness of the varicella vaccine in clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Loss of vaccine-induced immunity to varicella over time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Effectiveness over time of varicella vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Incidence of herpes zoster, 1997-2002.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Incidence of Herpes Zoster, Before and After Varicella‐Vaccination–Associated Decreases in the Incidence of Varicella, 1992–2002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Epidemiology of varicella zoster virus infection in Canada and the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Modelling the impact of vaccination on the epidemiology of varicella zoster virus in Australia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Social contacts and mixing patterns relevant to the spread of infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunisation programmes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Modelling the impact of one-dose vs. two-dose vaccination regimens on the epidemiology of varicella zoster virus in Australia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Using time-use data to parameterize models for the spread of close-contact infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Using empirical social contact data to model person to person infectious disease transmission: an illustration for varicella

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Contact patterns and their implied basic reproductive numbers: an illustration for varicella-zoster virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Changing varicella epidemiology in active surveillance sites--United States, 1995-2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

Most ten-year-old children with negative or unknown histories of chickenpox are immune

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.02.079

10.1016/J.VACCINE.2010.02.079

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20199763%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference